(Reuters) -Shares of Novavax Inc fell 16% after a report from Politico said the company faces significant hurdles in proving it can manufacture its experimental COVID-19 vaccine that meets regulators’ quality standards, resulting in production delays.FILE PHOTO: A vial and sryinge are seen in front of a displayed Novavax logo in this illustration taken January